Akeso's Chemotherapy-Free Lung Cancer Treatment Drastically Improves Patient Well-Being
Amsterdam, Tuesday 31 March 2026
Akeso’s new chemotherapy-free lung cancer treatment prevents health deterioration far longer than current standards, significantly reducing severe symptoms and presenting a highly compelling breakthrough for investors.
Redefining the Baseline for Lung Cancer Care
On 30 March 2026, Hong Kong-listed Akeso (9926.HK) revealed compelling exploratory analysis data from its HARMONi-2 study at the European Lung Cancer Congress (ELCC) [1]. The clinical trial evaluated the efficacy of ivonescimab against pembrolizumab as a first-line treatment for patients suffering from PD-L1–positive non-small cell lung cancer (NSCLC) [1]. In primary analyses, ivonescimab had already demonstrated superiority by delivering a median progression-free survival of 11.14 months, compared to 5.82 months for pembrolizumab, which equates to a 49 per cent reduction in the risk of disease progression or death [1].
Strategic Synergies and the IO 2.0 Frontier
Beyond its success in monotherapy applications, Akeso is aggressively advancing its proprietary “IO 2.0 + ADC 2.0” combination platform [2]. On 25 March 2026, the company received clearance from the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) to initiate Phase II clinical trials [2]. These mid-stage studies will evaluate novel antibody-drug conjugates (ADCs)—specifically AK146D1 and AK138D1—in combination with foundational backbone therapies like ivonescimab and cadonilimab across a spectrum of advanced solid tumours [2].
Global Regulatory Milestones Amidst Fierce Competition
The broader life sciences and health sector is witnessing a surge in lab-to-market transitions and regulatory milestones as the first quarter of 2026 concludes. On 30 March 2026, the US Food and Drug Administration (FDA) granted breakthrough therapy designation to Johnson & Johnson’s co-formulated bispecific antibody therapy for dual EGFR/MET targeting in HPV-negative head and neck cancer [3]. Concurrently, China approved Sciwind’s ecnoglutide for weight management, a move that intensifies competition in the lucrative global GLP-1 market alongside the firm’s commercialisation deal with Pfizer [3].
Navigating Macroeconomic Headwinds in Biopharma
These clinical and regulatory advancements are unfolding against a backdrop of severe macroeconomic and geopolitical volatility. Escalating conflict in the Middle East has severely disrupted global energy markets, with Yemen’s Houthis striking Israel with missiles and Iran effectively closing the Strait of Hormuz to most vessels—a chokepoint impacting a fifth of global oil and gas shipments [4]. Consequently, benchmark Brent crude opened at a staggering US$115.80 a barrel in New York on 30 March 2026 [4]. While Pakistan hosted a meeting on 30 March 2026 hoping to facilitate US-Iran negotiations in Karachi [4], the diplomatic outlook remains highly precarious [alert! ‘It remains uncertain if the proposed US-Iran negotiations in Karachi will materialise given the immediate escalation in hostilities and the arrival of 50,000 US troops in the region’].